Report 2018
Rethink Tomorrow
Report 2018

About the report

The Novozymes Report 2018 is available in the form of a full online version at report2018.novozymes.com. The online report features interactive graphics and videos for an even better experience and greater insight.

 

Editorial team

 

Editor-in-Chief
Anja Berg Winther, Global Communications 

abw@novozymes.com | tel. +45 3077 0421

 

Communications
Ann Lauritzen Steel, Global Communications 
alas@novozymes.com | tel. +45 3077 2027

Finance
Jens Breitenstein, Finance
jib@novozymes.com | tel. +45 3077 1087

Investor Relations
Carl Ahlgren, Investor Relations
cxal@novozymes.com | tel. +45 3077 2783

Sustainability
Santosh Govindaraju, Corporate Sustainability
govs@novozymes.com | tel. +45 3077 2563

 

Text
The editorial team from Novozymes, headed by Global Communications

 

Photography

Lars Just, Thorbjørn Hansen and Ty Stange 

 

Design & web

BystedFFW A/S

 

Editing & proofreading

Borella projects

 

Reporting and audits
The website contains The Novozymes Report 2018, which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company's annual report. It also contains the financial statements of the parent company Novozymes A/S. Together, these constitute the company’s annual report that is filed with the Danish Business Authority. 

 

PwC has audited the consolidated financial statements, the parent company financial statements, and the environmental and social data. PwC is also the sustainability assurance provider, basing its assurance on the AA1000 Assurance Standard (2008).

 

The audit covers the financial, environmental and social data. These are marked “Audited by PwC.” See also the statements in the report. 

 

PwC has not audited the sections of the report under the headings The big picture, Our business, Governance, and Sustainability. The Sustainability section includes our Communication on Progress made with respect to the UN Global Compact principles, our report index based on the Global Reporting Initiative (GRI) as well as detailed sustainability data regarding our main activities in Argentina, Brazil, Canada, China, Denmark, India and the US.

 

The report has been prepared in accordance with the International Financial Reporting Standards (IFRS), the Danish Financial Statements Act and the additional requirements of Nasdaq Copenhagen A/S for the presentation of financial statements by listed companies. It is also inspired by the GRI's G4 Sustainability Reporting Guidelines. See Basis of reporting in the report for more details.

Forward-looking statements
This annual report contains forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "could," "may," "might" and other words with a similar meaning.

 

Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations, both positively and negatively. These risks and uncertainties may include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes’ products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes’ core areas; iii) the ability to protect and enforce the company’s intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company’s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; and viii) significant price decreases for inputs and materials that compete with Novozymes’ biological solutions. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

 

Back to notes
Scroll to top